Kornimate/medical-research-clean huggingface dataset:
a research study looking at how semaglutide works in people with type 2 diabetes in denmark and sweden, as part of local clinical practice (sure denmark/sweden)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how semaglutide works in real world patients. participants will get semaglutide prescribed by the study doctor. the study will last for about 6 to 8 months. participants will be asked to complete some questionnaires about their health and diabetes treatment. participants will complete these questionnaires during their normally scheduled visits with the study doctor.


Eligibility criteria:
inclusion criteria: - signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) - the decision to initiate treatment with commercially available semaglutide has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study - male or female, age greater than or equal to 18 years at the time of signing informed consent - diagnosed with type 2 diabetes at least 12 weeks prior to inclusion -available and documented haemoglobin a1c (hba1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment exclusion criteria: - previous participation in this study. participation is defined as having given informed consent in this study - mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation - treatment with any investigational drug within 90 days prior to enrolment into the study - hypersensitivity to semaglutide or to any of the excipients
assessment of colonisation and skin quality parameter improvement by probiotic micrococcus luteus q24 balm in healthy adults.

Conditions: Microbial Colonization

Summary: the purpose of this study is to evaluate the skin quality improvement and colonization efficacy following the application of probiotic micrococcus luteus q24 (blis q24) to the elbow and back of forearm in a topical balm format in healthy adults.

this is a randomized double-blind, placebo-controlled pilot study with no crossover for the assessment of any changes to the microbial make-up of the skin (the local skin microbiome), detection of colonisation by the probiotic bacterium (blis q24) on the skin and to evaluate the changes in skin quality parameters following topical application of probiotic in a balm format.

Eligibility criteria:
inclusion criteria: * in general good health 18 - 80 years of age. * practice good general body hygiene exclusion criteria: * have a history of autoimmune disease or are immunocompromised. * are on concurrent antibiotic therapy or regular antibiotic use within the last 1 week. * people with allergies or sensitivity to dairy. * people with an open wound on the blis q24 application sites.

Keywords: probiotic
colloidal oatmeal, colloid cream, diaper rash, preterm neonates and neonatal intensive care unit

Conditions: Diaper Rash; Preterm Neonates

Summary: -this study aimed to investigate the effect of colloid oatmeal compared to colloid cream on diaper rash among preterm neonates in the nicu.

a quasi-experimental study was carried out in the nicu of el-raml children's hospital at wengat in alexandria. ninety preterm neonates were randomly assigned to three equal groups. the control group received the usual care of nicu for diaper rash, colloidal oatmeal group received colloidal oatmeal cream and colloid group received colloid cream (cold which is the base for colloid oatmeal)

Eligibility criteria:
inclusion criteria: * preterm neonates * have diaper rash, * hemodynamically stable * receive enteral feeding (breast, bottle, gavage, or mixed feeding) * newly admitted to the previously mentioned setting * on the first day of exposure to diaper rash exclusion criteria: * preterm who have candida infection in groin * use other drugs for diaper rash

Keywords: colloidal oatmeal diaper rash preterm neonates
problem-solving therapy for depressive symptoms and quality of life in stroke survivor-caregiver dyads

Conditions: Stroke; Quality of Life; Depression

Summary: the purpose of this feasibility study is to determine whether it is practical and helpful to provide problem-solving therapy to stroke survivors and their spouses/partners (caregivers) together. it will also compare the experiences of participants who receive problem-solving therapy to those who receive stroke-related health education. many stroke survivors and caregivers report feeling sad or blue at some point after the stroke. these feelings can impact quality of life. encountering problems is a part of daily life. these problems can be big or small, but sometimes they can pile up and feel overwhelming, contributing to feelings of sadness. problem-solving therapy is a tool that teaches structured ways to address current problems or challenges in your life. participants who are assigned to receive problem-solving therapy will work with a research team member for six, one-hour sessions. during each session, participants will identify a problem (big or small) and create a plan to work on that problem. participants who are assigned to receive stroke-related health education will work with a research team member who will teach them about various topics related to stroke over six, one-hour sessions. each session will cover information about a different topic related to stroke. outcomes data will be collected at approximately 4 weeks, 8 weeks, and 13 weeks from baseline.


Eligibility criteria:
inclusion criteria: 1. both dyad participants are at least 18 years of age. 2. the stroke survivor experienced an ischemic or hemorrhagic stroke at least 3 months prior to enrollment. 3. the caregiver is a spouse/partner who provides regular, unpaid support for the survivor in activities of daily living. 4. both dyad members are willing and able understand and comply with protocol requirements. exclusion criteria: 1. the stroke survivor has severe expressive or receptive aphasia or global aphasia, as documented in the medical record by a speech pathologist or other provider. 2. either dyad member is unable to write, as this will interfere with completion of minicog assessment. 3. either dyad member has significant cognitive impairment, evidenced by minicog score \<4 at screening. 4. either dyad member reports an intent to harm him/herself or others. 5. either dyad member has any concurrent conditions that would interfere with participation.
e7070 in treating patients with solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase i trial to study the effectiveness of e7070 in treating patients who have solid tumors.

objectives: * determine the maximum tolerated dose (mtd) of e7070 when administered to adult patients with solid tumors. * determine the qualitative and quantitative toxic effects of this drug and study the predictability, duration, intensity, onset, reversibility and dose relationship of the toxic effects in this patient population. * propose a safe dose for phase ii study. * assess the pharmacokinetics of this drug at different dose levels in this patient population. * determine any possible antitumor activity of this drug in this patient population. outline: this is a dose escalation study. patients receive e7070 iv over 1 hour on days 1, 8, 15, and 22. treatment continues every 6 weeks for at least 2 courses in the absence of unacceptable toxicity or disease progression. cohorts of 3-6 patients receive escalating doses of e7070 is escalated until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. patients are followed every 3 weeks. projected accrual: a total of 30 patients will be accrued for this study over 12 months.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed solid tumor that is not amenable to standard therapy * no brain involvement or leptomeningeal disease patient characteristics: age: * 18 and over performance status: * who 0-2 life expectancy: * at least 3 months hematopoietic: * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 * hemoglobin at least 9 g/dl hepatic: * bilirubin less than 1.5 mg/dl * liver function tests no greater than 2.5 times upper limit of normal (uln) (no greater than 5 times uln if liver metastases present) renal: * creatinine no greater than 1.4 mg/dl or * creatinine clearance at least 60 ml/min other: * not pregnant or nursing * fertile patients must use effective contraception * no active bacterial infections (e.g., abscess or fistulae) * no other nonmalignant disease that precludes protocol therapy * no history of alcoholism, drug addiction, or psychotic disorders that preclude participation * no glaucoma prior concurrent therapy: biologic therapy: * at least 4 weeks since prior immunotherapy chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) * no other concurrent antitumor drugs endocrine therapy: * at least 4 weeks since prior anticancer hormonal therapy radiotherapy: * at least 4 weeks since prior radiotherapy (6 weeks for extensive radiotherapy) * no concurrent radiotherapy (except localized palliative radiotherapy) surgery: * not specified other: * no concurrent sulfonylurea agent for diabetes or antiarrhythmic agents * no other concurrent investigational drugs

Keywords: unspecified adult solid tumor, protocol specific
concomitant radiation and cisplatin with and without tirapazamine in treatment of advanced head and neck cancer

Conditions: Head and Neck Neoplasms

Summary: the trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.


Eligibility criteria:
inclusion criteria: * previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. * stage iii or iv disease (excluding t1n1, and t2n1). * ecog performance status less than or equal to 2. * absolute neutrophil count at least 1.5 x 10\^9/l, platelet count at least 100 x 10\^9/l, and hemoglobin \> 9g/dl. * serum bilirubin \< 1.25 times uln and ast/alt \< 2.5 times uln. * calculated creatinine clearance (cockcroft-gault) \> 55 ml/min. exclusion criteria: * metastatic disease

Keywords: squamous cell carcinoma oropharynx oral cavity larynx hypopharynx
treatment for women with post-traumatic stress disorder related to childhood abuse

Conditions: Stress Disorders, Post-Traumatic

Summary: this study will compare one- and two-component treatments in women with post-traumatic stress disorder (ptsd).

ptsd is a debilitating and often chronic anxiety disorder with serious psychiatric comorbidity. the most common trauma associated with ptsd among women is childhood abuse. ptsd related to childhood abuse may cause problems with emotion regulation and interpersonal functioning. this study will address three domains of ptsd related to childhood abuse: emotion management problems, interpersonal problems, and ptsd symptoms. participants in this study will be randomly assigned to 16 sessions of one of three treatments: skills training for affective and interpersonal regulation (stair), which focuses on helping individuals strengthen and build skills in managing feelings and improving interpersonal relationships; modified prolonged exposure (mpe), which focuses on developing narratives of abuse history and completing an "emotional processing" of the trauma in a safe environment; and a combination of stair and mpe. dropout rates and adverse effects will be measured.

Eligibility criteria:
inclusion criteria: * dsm-iv criteria for post-traumatic stress disorder related to childhood physical and/or sexual abuse by a care-giver * at least one clear memory of the abuse * willing to have all assessments tape recorded and sessions video taped * willing to maintain any concurrent treatments for the duration of the study exclusion criteria: * bipolar disorder * eating disorder * borderline personality disorder * active substance abuse or dependence * living with the abuser * self mutilation * pregnancy
study of effectiveness of telemedicine in identifying diabetic retinopathy cases

Conditions: Diabetic Retinopathy

Summary: the aim of this study is to compare the effectiveness of identifying diabetic retinopathy using tele-medicine based digital retinal imaging in diabetes clinics with that of the conventional referral system. hypothesis: tele-medicine based digital retinal imaging involving a diabetes centre will identify proportionately more diabetic patients with dr and lead to higher acceptance rate with subsequent ophthalmic referral and management

the design is a cluster randomized trial of tele-medicine versus usual care in diabetic patients. the primary outcome of the study is the proportion of patients with confirmed dr at aravind eye hospital (aeh). dr will be graded using the international clinical diabetic retinopathy disease severity scale. a sample size of 616 patients in both arms is required to detect a risk ratio of 1.8 or above at 90% power, 1% alpha and a design effect of 2. eight clinics will be recruited and equally randomized to tele-medicine or usual care stratified by distance from aeh. inclusion criteria include a confirmed diagnosis of diabetes, age over 50, no retinal exam in the previous year. in the tele-medicine arm patients will be offered fundus imaging and patients diagnosed with dr or probable dr will be counselled to visit aeh to confirm dr. in the usual care arm, the eligible patients will be counselled and referred to undergo an eye examination at aeh. in both the arms the counselling and the awareness creation materials will be standardized. fundus imaging will be offered at the end of the study to those who refuse initially and all those in the usual arm who did not attend aeh.

Eligibility criteria:
inclusion criteria: * diabetic patients (as per icd-9 code 250) in the age group of ≥50 years exclusion criteria: * patients \<50 years of age * already enrolled as study patients at the diabetes centre * patients screened for dr in free camps organized by the diabetes centre * diabetic patients who underwent retinal examination in the previous year prior to this intervention * patients with disability (physical or mental) who have difficulty in travelling to the eye hospital

Keywords: diabetic retinopathy screening tele-medicine retinal imaging remote diagnosis
standardized goal-directed vs. self-directed valsalva maneuver for the assessment of patent foramen ovale

Conditions: Stroke

Summary: ischemic stroke represents a major public health issue, leading to significant disabilities and deaths worldwide. when no clear cause for stroke is found following a comprehensive cardiovascular evaluation (no atrial fibrillation, cardiac masses, or atherosclerosis) i.e. cryptogenic stroke, it is recommended to search for a patent foramen ovale (pfo), especially in young patients. it is estimated that cryptogenic stroke accounts for 30% to 40% of ischemic strokes. transthoracic echocardiography (tte) with bubble study at rest and during valsalva maneuver is the reference method for the diagnosis of pfo. the treatment of pfo using a closure device has demonstrated a significant reduction in recurrent stroke events in patients with pfo and cryptogenic stroke. the valsalva maneuver is currently achieved using self-directed maneuver i.e. patients are instructed to ''bear down'' or ''strain as if attempting to move your bowels.'' these instructions are subjective and depend largely on individuals understanding and effort. a goal-directed valsalva maneuver using a manometer has been shown to be a more reproducible way to perform the valsalva achieving more sensitivity in different settings such as hypertrophic cardiomyopathy but its incremental diagnostic value for the detection of pfo has not been yet evaluated. the aim of the present study is to compare the sensibility and specificity of two methods of valsalva maneuver for the detection of pfo. we hypothesize that goal-directed valsalva maneuver will significantly increase the detection rate of pfo compared to self-directed valsalva maneuver.


Eligibility criteria:
inclusion criteria: * patients referred for a clinically indicated tte and bubble study exclusion criteria: * inability to provide informed consent * inability to insert an iv line * inability to perform a self-directed valsalva maneuver * patient wishing to keep his mask on

Keywords: bubble study stroke echocardiography patent foramen ovale
occlusive dressing vs palmar pedicular island flap in fingertip amputation

Conditions: Finger Injuries

Summary: our study aims to prospectively compare outcomes of conservative treatment (occlusive dressing) to surgery with a palmar bipedicled island flap (modified tranquilli-leali flap) in the management of allen zones ii-iii-iv fingertip injuries in long fingers. based on these results, the investigators intend to help provide guidelines to optimize the management, and eventually the satisfaction of these patients.

the investigators intend to conduct a prospective tricentric (hand surgery service in chuv( centre hospitalier universitaire vaudois, lausanne/ hand surgery service in hug (hôpitaux universitaire de genève and hand surgery service in valais hospital, sierre), open-label, randomized controlled trial: occlusive dressing versus surgery in fingertips amputation. the investigators will collect demographic data and informations about the injury including age, sex, medical history and daily medications, occupation, dominant hand, active smoking, mechanism of injury, associated injuries, time from injury to management, size and geometry (volar/transverse/dorsal) of defect, level of amputation (allen classification), injury and repair of the nail bed. patients will be randomized into the occlusive dressing group or the surgical group on their first visit to the hand surgery department. both groups will have 6 months and 1-year follow-up appointment, including ultrasound evaluation.

Eligibility criteria:
inclusion criteria: * patients \> 18 years old * allen zones ii-iii-iv long finger amputation. * trauma \< 48h. exclusion criteria: * patients who are not able to give consent * injuries involving the dip joint, extensor apparatus or requiring osteosynthesis. * chronic dermatological disorders of the hand, immunosuppressive drugs or chemotherapy. - patient without a consent form would be excluded.
trastuzumab plus chemotherapy in treating patients with advanced non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. purpose: phase ii trial to study the effectiveness of the monoclonal antibody trastuzumab plus carboplatin and paclitaxel in treating patients who have advanced non-small cell lung cancer.

objectives: i. assess the toxicity of monoclonal antibody her2 with carboplatin and paclitaxel in patients with her2 positive non-small cell lung cancer. ii. determine median time to progression and one year freedom from progression in this patient population. iii. evaluate one year survival rate and overall objective response rate in this patient population. outline: patients receive paclitaxel iv over 3 hours immediately followed by carboplatin iv over 30 minutes immediately followed by monoclonal antibody her2 iv over 30-90 minutes on day 1. patients also receive monoclonal antibody her2 on days 8 and 15. treatment is repeated every 3 weeks for 6 courses. after 6 courses of treatment, patients may receive monoclonal antibody her2 weekly for up to 1 year in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 2 years, every 6 months for 3 years and once a year thereafter until disease progression or death. projected accrual: a total of 22-44 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed non-small cell lung cancer (nsclc) recurrent and/or stage iiib with pleural or pericardial effusion or stage iv must have at least one bidimensionally measurable lesion must be her2 positive (1-3+) brain metastases allowed, if symptoms controlled and not requiring steroids prior/concurrent therapy-- biologic therapy: not specified chemotherapy: no prior chemotherapy for nsclc endocrine therapy: no concurrent steroids radiotherapy: at least 2 weeks since prior radiotherapy surgery: not specified patient characteristics: age: 18 and over performance status: ecog 0-1 life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl transaminases no greater than 5 times upper limit of normal renal: creatinine no greater than 2 mg/dl cardiovascular: no uncontrolled angina pectoris and arrhythmias no myocardial infarction within past 3 months no uncompensated congestive heart failure ejection fraction at least 45% other: no active infections not pregnant or nursing fertile patients must use effective contraception hiv negative no other active malignancies no evidence of peripheral sensory neuropathy of at least grade 2

Keywords: recurrent non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer